 <h1>Tarabine PFS Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>cytarabine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about cytarabine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Tarabine PFS.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cytarabine: parenteral conventional cytarabine injection, parenteral conventional cytarabine powder for injection, parenteral liposomal cytarabine injection</i></p><h3>Warning</h3><p><ul>
Experience of Supervising Clinician
<li>
Conventional cytarabine: Use only under supervision of qualified clinicians experienced in therapy with antineoplastic agents.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;j&lt;/sup&gt;  Consider possible benefits vs known risks of cytarabine treatment.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;j&lt;/sup&gt;</li></ul></p><ul>
Experience of Supervising Clinician
<li>
Conventional cytarabine: Use only under supervision of qualified clinicians experienced in therapy with antineoplastic agents.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;j&lt;/sup&gt;  Consider possible benefits vs known risks of cytarabine treatment.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;j&lt;/sup&gt;</li></ul><p>
<li>
Liposomal cytarabine: Use only under supervision of qualified clinicians experienced in <i>intrathecal</i> therapy with antineoplastic agents; adequate diagnostic and treatment facilities must be readily available for management of complications.&lt;sup&gt;d&lt;/sup&gt;</li></p><p>
<ul>
Induction Therapy with Conventional Cytarabine
<li>
Patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;j&lt;/sup&gt;</li></ul></p><ul>
Induction Therapy with Conventional Cytarabine
<li>
Patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;j&lt;/sup&gt;</li></ul><p>
<li>
Risk of serious adverse effects, including myelosuppression with leukopenia, thrombocytopenia, and anemia.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;j&lt;/sup&gt;  Less serious adverse effects include nausea, vomiting, diarrhea, abdominal pain, oral ulceration, and hepatic dysfunction.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;c&lt;/sup&gt; &lt;sup&gt;j&lt;/sup&gt;  (See Cautions.)</li></p><p>
<ul>
Chemical Arachnoiditis with Intrathecal Liposomal Cytarabine
<li>
Chemical arachnoiditis, a syndrome manifested principally by nausea, vomiting, headache, and fever, commonly occurs.&lt;sup&gt;d&lt;/sup&gt;  If left untreated, may be fatal.&lt;sup&gt;d&lt;/sup&gt;  (See Chemical Arachnoiditis Related to Liposomal Cytarabine under Cautions.)</li></ul></p><ul>
Chemical Arachnoiditis with Intrathecal Liposomal Cytarabine
<li>
Chemical arachnoiditis, a syndrome manifested principally by nausea, vomiting, headache, and fever, commonly occurs.&lt;sup&gt;d&lt;/sup&gt;  If left untreated, may be fatal.&lt;sup&gt;d&lt;/sup&gt;  (See Chemical Arachnoiditis Related to Liposomal Cytarabine under Cautions.)</li></ul><p>
<li>
Administer dexamethasone to ameliorate symptoms and reduce incidence.&lt;sup&gt;d&lt;/sup&gt;  (See Liposomal Cytarabine under Dosage and Administration.)</li></p><p></p><p>Side effects include:</p><p>IV, sub-Q, or IM administration of conventional cytarabine (the active ingredient contained in Tarabine PFS)  Myelosuppression, anorexia, nausea, vomiting, diarrhea, oral and anal inflammation or ulceration, hepatic dysfunction, fever, rash, thrombophlebitis, bleeding (all sites).    </p><p>Intrathecal administration of conventional cytarabine: Nausea, vomiting, fever, transient headaches.      </p><p>Intrathecal administration of liposomal cytarabine: Chemical arachnoiditis (neck rigidity, neck pain, meningism, nausea, vomiting, headache, fever, back pain, and/or CSF pleocytosis), asthenia, pain, confusion, somnolence.  </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cytarabine: injectable powder for injection, injectable solution</i></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Hemorrhagic conjunctivitis, corneal disorder</p><p><b>Common</b> (1% to 10%): Photophobia, burning, visual disturbance, increased lacrimation, keratitis</p><p><b>Uncommon</b> (0.1% to 1%): Conjunctivitis</p><p><b>Frequency not reported</b>: Blindness<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Somnolence</p><p><b>Common</b> (1% to 10%): Decreased level of consciousness, dysarthria, nystagmus</p><p><b>Uncommon</b> (0.1% to 1%): Neurotoxicity, neuritis, dizziness, headache, peripheral neuropathy, paraplegia (with intrathecal administration) </p><p><b>Frequency not reported</b>: Dizziness, neurotoxicity rash, coma, convulsion, peripheral sensory neuropathy, ataxia, tremor, coma, convulsions<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Chest pain</p><p><b>Very rare</b> (less than 0.01%): Arrhythmia</p><p><b>Frequency not reported</b>: Pericarditis, cardiomyopathy<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Bone marrow failure, thrombocytopenia, anemia, megaloblastic anemia, leukopenia, reticulocyte count decreased</p><p><b>Common</b> (1% to 10%): Bleeding (all sites), thrombophlebitis</p><p><b>Frequency not reported</b>: Reticulocytopenia, neutropenia, febrile neutropenia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylactic reaction, allergic edema<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Sepsis, infection</p><p><b>Frequency not reported</b>: Viral, bacterial, fungal, parasitic, or saprophytic infections, in any location in the body (sometimes fatal)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site cellulitis, injection site thrombophlebitis</p><p><b>Frequency not reported</b>: Injection site pain, injection site inflammation, injection site irritation, injection site sepsis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Cytarabine (the active ingredient contained in Tarabine PFS) syndrome (e.g., fever, myalgia, bone pain, occasionally chest pain, exanthema, maculopapular rash, conjunctivitis, nausea, malaise)</p><p><b>Uncommon</b> (0.1% to 1%): Myalgia, joint pain<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia, hyperuricemia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Personality change, confusion<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Urinary retention</p><p><b>Frequency not reported</b>: Amenorrhea, azoospermia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Hepatic function abnormal</p><p><b>Common</b> (1% to 10%): Liver enzymes increased</p><p><b>Uncommon</b> (0.1% to 1%): Jaundice</p><p><b>Frequency not reported</b>: Liver abscess, hyperbilirubinemia, hepatomegaly, Budd-Chiari-syndrome (hepatic venous thrombosis)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Pneumonia, acute respiratory distress syndrome, pulmonary edema</p><p><b>Uncommon</b> (0.1% to 1%): Shortness of breath<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Renal dysfunction<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia, rash</p><p><b>Common</b> (1% to 10%): Skin ulceration, erythema, bullous dermatitis, vasculitis</p><p><b>Uncommon</b> (0.1% to 1%): Lentigo, palmar-plantar erythrodysesthesia syndrome, urticaria, pruritus, freckling, burning pain of palms and soles</p><p><b>Very rare</b> (less than 0.01%): Neutrophilic eccrine hidradenitis</p><p><b>Frequency not reported</b>: Skin bleeding<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Stomatitis, mouth ulceration, anal ulcer, anal inflammation, diarrhea, vomiting, nausea, abdominal pain</p><p><b>Common</b> (1% to 10%): Necrotizing colitis</p><p><b>Uncommon</b> (0.1% to 1%): Sore throat, esophagitis, esophageal ulceration, bowel necrosis</p><p><b>Frequency not reported</b>: Pancreatitis, bowel necrosis, GI ulcer, pneumatosis intestinalis, peritonitis, mucosal bleeding<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Cytarabine (cytarabine)." Hospira Inc, Lake Forest, IL. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What drugs are contained in Vyxeos?</li>
</ul><h2>More about Tarabine PFS (cytarabine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: antimetabolites</li>
<li>FDA Alerts (3)</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Myeloid Leukemia</li>
<li>Acute Nonlymphocytic Leukemia</li>
<li>Leukemia</li>
<li>Meningeal Leukemia</li>
<li>Non-Hodgkin's Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>